Kamada closed at $8.13 on Nov 12, unchanged, 12.7% below its 52-week closing high. Volume of 91.4K shares was 0.82× its 20-day average (close to normal).
Split-adjusted performance: +7.0% over one month, +1.3% over six months, +15.2% over one year.
Short interest was 165.8K shares at the Oct 30 settlement, down 16.1% from the prior report (0.5% of float, 2.6 days to cover).
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology.
What is KMDA's market cap?
$469.36M, based on the Nov 12 close of $8.13.
Does Kamada pay a dividend?
Yes. The latest regular dividend was $0.17 per share (ex-date Aug 27), an annualised yield of 2.09%.
How much of KMDA is sold short?
165.8K shares, 0.5% of float, as of Oct 30, 2026.
About Kamada
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
